IBDEI0NH ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10730,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,10730,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,10731,0)
 ;;=D56.2^^68^675^52
 ;;^UTILITY(U,$J,358.3,10731,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10731,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,10731,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,10731,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,10732,0)
 ;;=D75.9^^68^675^53
 ;;^UTILITY(U,$J,358.3,10732,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10732,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
 ;;^UTILITY(U,$J,358.3,10732,1,4,0)
 ;;=4^D75.9
 ;;^UTILITY(U,$J,358.3,10732,2)
 ;;=^5002393
 ;;^UTILITY(U,$J,358.3,10733,0)
 ;;=D59.0^^68^675^56
 ;;^UTILITY(U,$J,358.3,10733,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10733,1,3,0)
 ;;=3^Drug-Induced Autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,10733,1,4,0)
 ;;=4^D59.0
 ;;^UTILITY(U,$J,358.3,10733,2)
 ;;=^5002323
 ;;^UTILITY(U,$J,358.3,10734,0)
 ;;=D59.2^^68^675^57
 ;;^UTILITY(U,$J,358.3,10734,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10734,1,3,0)
 ;;=3^Drug-Induced Nonautoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,10734,1,4,0)
 ;;=4^D59.2
 ;;^UTILITY(U,$J,358.3,10734,2)
 ;;=^5002325
 ;;^UTILITY(U,$J,358.3,10735,0)
 ;;=R59.9^^68^675^60
 ;;^UTILITY(U,$J,358.3,10735,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10735,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Unspec
 ;;^UTILITY(U,$J,358.3,10735,1,4,0)
 ;;=4^R59.9
 ;;^UTILITY(U,$J,358.3,10735,2)
 ;;=^5019531
 ;;^UTILITY(U,$J,358.3,10736,0)
 ;;=D47.3^^68^675^61
 ;;^UTILITY(U,$J,358.3,10736,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10736,1,3,0)
 ;;=3^Essential Thrombocythemia
 ;;^UTILITY(U,$J,358.3,10736,1,4,0)
 ;;=4^D47.3
 ;;^UTILITY(U,$J,358.3,10736,2)
 ;;=^5002258
 ;;^UTILITY(U,$J,358.3,10737,0)
 ;;=C82.09^^68^675^62
 ;;^UTILITY(U,$J,358.3,10737,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10737,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,10737,1,4,0)
 ;;=4^C82.09
 ;;^UTILITY(U,$J,358.3,10737,2)
 ;;=^5001470
 ;;^UTILITY(U,$J,358.3,10738,0)
 ;;=C82.00^^68^675^63
 ;;^UTILITY(U,$J,358.3,10738,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10738,1,3,0)
 ;;=3^Follicular Lymphoma Grade I,Unspec Site
 ;;^UTILITY(U,$J,358.3,10738,1,4,0)
 ;;=4^C82.00
 ;;^UTILITY(U,$J,358.3,10738,2)
 ;;=^5001461
 ;;^UTILITY(U,$J,358.3,10739,0)
 ;;=C82.19^^68^675^64
 ;;^UTILITY(U,$J,358.3,10739,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10739,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,10739,1,4,0)
 ;;=4^C82.19
 ;;^UTILITY(U,$J,358.3,10739,2)
 ;;=^5001480
 ;;^UTILITY(U,$J,358.3,10740,0)
 ;;=C82.10^^68^675^65
 ;;^UTILITY(U,$J,358.3,10740,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10740,1,3,0)
 ;;=3^Follicular Lymphoma Grade II,Unspec Site
 ;;^UTILITY(U,$J,358.3,10740,1,4,0)
 ;;=4^C82.10
 ;;^UTILITY(U,$J,358.3,10740,2)
 ;;=^5001471
 ;;^UTILITY(U,$J,358.3,10741,0)
 ;;=C82.29^^68^675^66
 ;;^UTILITY(U,$J,358.3,10741,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10741,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,10741,1,4,0)
 ;;=4^C82.29
 ;;^UTILITY(U,$J,358.3,10741,2)
 ;;=^5001490
 ;;^UTILITY(U,$J,358.3,10742,0)
 ;;=C82.20^^68^675^67
 ;;^UTILITY(U,$J,358.3,10742,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10742,1,3,0)
 ;;=3^Follicular Lymphoma Grade III,Unspec Site
 ;;^UTILITY(U,$J,358.3,10742,1,4,0)
 ;;=4^C82.20
 ;;^UTILITY(U,$J,358.3,10742,2)
 ;;=^5001481
 ;;^UTILITY(U,$J,358.3,10743,0)
 ;;=C82.39^^68^675^68
 ;;^UTILITY(U,$J,358.3,10743,1,0)
 ;;=^358.31IA^4^2
